Charles E. Gale is Director & 10% Owner at REATA PHARMACEUTICALS INC (RETA). They have made 1 open-market trade across 1 company since 2016, most recently 2018-11-13.
CIK 0001675029
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $12.1M since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RETA | 879,281 | $151.6M |
Shares reported on the most recent Form 4, priced at the 2018-11-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RETA | BUY | 2016-06-01 | 2016-06-02 | $11.00 | $12.1M | +37.2% | +12.0% | +20.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.